Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Abstract
The lateral segment of the globus pallidus (GPl) is thought to be overactive in levodopa-induced dyskinesia in PD. Stimulation of cannabinoid receptors in the GPl reduces γ-aminobutyric acid (GABA) reuptake and enhances GABA transmission and may thus alleviate dyskinesia. In a randomized, double-blind, placebo-controlled, crossover trial (n = 7), the authors demonstrate that the cannabinoid receptor agonist nabilone significantly reduces levodopa-induced dyskinesia in PD.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
File (sieradzan.doc)
- Download
- 39.50 KB
References
1.
Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson’s disease. Mov Disord . 1998; 13: 871–876.
2.
Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia. Ann Neurol . 2000; 47 (suppl 1): 105–114.
3.
Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson’s disease: implications for future strategies in treatment. Mov Disord . 1990; 5: 100–108.
4.
Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann Neurol . 2000; 47 (suppl 1): 22–34.
5.
Mailleux P, Parmentier M, Vanderhaeghen JJ. Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett . 1992; 143: 200–204.
6.
Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol . 1996; 308: 161–164.
7.
Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord . 1992; 7: 2–13.
8.
Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson’s disease: inter- and intrarater reliability assessment. Mov Disord . 1994; 9: 390–394.
9.
Webster DD. Critical analysis of the disability in Parkinson’s disease. Mod Treat . 1968; 5: 257–282.
Information & Authors
Information
Published In
Copyright
© 2001.
Publication History
Received: June 18, 2001
Accepted: August 20, 2001
Published in issue: December 1, 2001
Published online: December 11, 2001
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Therapeutic effects of cannabinoids on Parkinson’s disease: an updated systematic review and meta-analysis of randomized controlled trials, Acta Neurologica Belgica, (2026).https://doi.org/10.1007/s13760-026-03082-0
- The role of cannabinoid ligands in neurodegenerative diseases: Emerging anti-inflammatory, immunomodulation and disease-modifying perspectives, Pharmacological Research, 227, (108185), (2026).https://doi.org/10.1016/j.phrs.2026.108185
- Cannabinoids and cognition in Parkinson’s disease: Insights from animal models and emerging clinical evidence, Neuroscience, 603, (37-49), (2026).https://doi.org/10.1016/j.neuroscience.2026.03.023
- Cannabinoids in Motor Control: From Receptor Distribution to Motor Disorders, Biomedicines, 14, 4, (844), (2026).https://doi.org/10.3390/biomedicines14040844
- The Effects of Therapeutic Cannabis and Cannabinoids in Parkinson’s Disease: An Overview of Meta-Analyses, The 2nd International Electronic Conference on Medicine, (3), (2026).https://doi.org/10.3390/msf2026043003
- Gamma-aminobutyric acid associated research in Parkinson’s disease: an exploratory trends analysis, Frontiers in Aging Neuroscience, 17, (2026).https://doi.org/10.3389/fnagi.2025.1655660
- Development of cannabinoid-based therapies for Parkinson’s disease: emphasis on targeting cannabinoid receptors as CB2, PPAR-γ and GPR55 receptors, Molecular Neurodegeneration Advances, 2, 1, (2026).https://doi.org/10.1186/s44477-025-00016-7
- The cannabinoid CB2 receptor: improvement of sleep or memory in rotenone model of Parkinson's disease, European Journal of Pharmacology, 1000, (177745), (2025).https://doi.org/10.1016/j.ejphar.2025.177745
- The Therapeutic Potential and Ethical Implications of Medical Cannabis in Parkinson's Disease: Exploring Mitigation of Reliance on Deep Brain Stimulation, International Journal of Innovative Science and Research Technology, (3483-3486), (2025).https://doi.org/10.38124/ijisrt/25apr1989
- Pipeline of Pharmacotherapy in Parkinson’s Disease, International Compendium of Movement Disorders, (290-305), (2025).https://doi.org/10.1017/9781108989855.026
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
